Skip to content
  • Reports
  • Podcast
  • Log In

Now covering the global biotech industry!
Read More
Topics
  • CRISPR
  • CAR-T
  • Covid-19
  • Microbiome
  • mRNA technology
  • Gene therapy
  • CRISPR
  • CAR-T
  • Covid-19
  • Microbiome
  • mRNA technology
  • Gene therapy
  • Log In
Now covering the global biotech industry!
Read More

Home » What’s new » Poxel

Poxel

ADVERTISEMENT
News and Trends

Poxel’s Diabetes Drug Wins Japan Nod, But Competition Remains Fierce

As French biotech Poxel marks the first market approval of its oral type 2 diabetes…

By Anita Chakraverty
02/07/2021 - 5 minutes
Best in Biotech

The Top 10 Biotechs You’ll Find in Lyon

Lyon is one of the hotspots for biotech in Europe. Here are 10 of the…

By Clara Rodríguez Fernández
10/07/2019 - 6 minutes
News and Trends

French First-in-Class Diabetes Drug Nails Phase III Trial

An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown…

By Jonathan Smith
09/04/2019 - 3 minutes
News and Trends

French Biotech Takes its Oral Diabetes Drug to Phase III

Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug…

By Melanie De Almeida
13/03/2018 - 3 minutes
News and Trends

Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide

Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development…

By Alex Dale
12/02/2018 - 3 minutes
News and Trends

Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia?

Try as we might, we can't cover all the biotech news out there. During the…

By Evelyn Warner
09/12/2016 - 2 minutes
News and Trends

Poxel raises €26.5M to support Phase III trial in Diabetes

Poxel has closed a capital increase on the Euronext Paris, raising €26.5M. The money is…

By Denise Neves Gameiro
19/07/2016 - 2 minutes
News and Trends

Poxel is Looking towards Japan’s Lucrative Diabetes Market

Poxel, the French company that made a €27M IPO last February,  announced the successful conclusion…

By Joachim Eeckhout
29/05/2015 - 2 minutes
News and Trends

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Poxel continues to interest the market after its successful IPO in February 2015, where it…

By Joachim Eeckhout
03/05/2015 - 3 minutes
footer logo

Labiotech.eu is the leading digital media covering the global biotech industry.

Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you’ll enjoy reading our stories!

  • About us
  • Inside Labiotech
  • Join Us
  • Advertise
  • Contact
  • Editorial Calendar
  • Site Map
  • Linkedin
  • Twitter
  • Youtube
  • RSS Feed
Made with in Berlin. Labiotech UG, All Rights Reserved -
  • Imprint
  • Privacy Policy

Browse Topics

Search for a topic, country or company name by using the search box

    Popular topics:


    CRISPR mRNA technology CAR-T HIV Cell therapy Diabetes Microbiome Startups Gene therapy Synthetic biology
    Labiotech.eu
    Log In Newsletter

    Topics

    • Gene Therapy
    • CRISPR
    • CAR-T
    • Covid-19
    • Microbiome
    • Diabetes
    • Cancer

    Sections

    • News and Trends
    • In Depth
    • Best in Biotech
    • Opinion
    • Interview
    • Infographics
    Show All Topics

    For Members

    • Expert Advice
    • Reports
    • Startup Scout

    More

    • About us
    • Inside Labiotech
    • Join Us
    • Advertise
    • Contact
    • Podcast